ГЕНЕТИЧЕСКИЕ МАРКЕРЫ КЛИНИЧЕСКИ ВЫРАЖЕННЫХ НЕЖЕЛАТЕЛЬНЫХ ЯВЛЕНИЙ У БОЛЬНЫХ С ВИЧ-ИНФЕКЦИЕЙ, ПОЛУЧАЮЩИХ АНТИРЕТРОВИРУСНУЮ ТЕРАПИЮ
V G Kanestri, К. О. Миронов, Aleksei V. Kravchenko et al. · HIV Infection and Immunosuppressive Disorders · 2014
The presence of the alleles UGT1A1*28 and HLA B*5701 was checked up in 47 and 366 adult HIV patients, respectively. The rate and severity of the adverse effects of using Atazanavir or Abacavir in ART during 2003-2013 were compared with the genetic findings. The prevalences of grade 3 or 4 increases in unconjugated bilirubin and of overt jaundice upon ART were 36,2% and 10.6%, respectively. The highest risk of profound hyperbilirubinemia was featured by patients homozygotic for UGT1A1*28. This allele was found in 57,4% of patients, including 14,9% homozygotes. HLA B*5701 was found in 13 patients (3,7%). Taking account of testing results decreased the rate of ART discontinuation to 4,7%. The specificity of the test was 100% and its sensitivity and informativeness was 99,2%.
Cited by 1 works. doi:10.22328/2077-9828-2014-6-2-49-57
Authors
- V G Kanestri
- К. О. Миронов
- Aleksei V. Kravchenko
- Anastasia V. Pokrovskaya
- Киреев Дмитрий Евгеньевич
- О. П. Дрибноходова
- Елена Алексеевна Дунаева
- Г. М. Цыганова
- Марина Александровна Харбутли
- Голиусова Марина Дмитриевна
- Vladislav V. Konnov
- Н. В. Козырина
- Шахгильдян Василий Иосифович
- У. А. Куимова
- А. А. Попова
- Оксана Станиславовна Ефремова
- Danila Konnov